StreetInsider.com News Articles

RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%

Tue, 17 Feb 2026 12:18:00 -0500

Consolidated net revenue of € 2,618.4 million for full year 2025, +11.8% or +8.3% on a like-for-like basis(3) at constant exchange rates (CER)
EBITDA(1) of € 991.1 million, +14.5%, margin on net revenue of 37.8%
Adjusted net income(2) of € 651.1 million, +14.5%, margin on net revenue of 24.9%
Net income of € 443.6 million, +6.5%
Free cash flow(4) of € 558.8 million, +€ 23.7 million reflecting strong EBITDA partially offset by U.S. inventory build-up, higher interests and income tax paid
Net debt(5) at € 2,037.3

RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%

Tue, 17 Feb 2026 12:18:00 -0500

Consolidated net revenue of € 2,618.4 million for full year 2025, +11.8% or +8.3% on a like-for-like basis(3) at constant exchange rates (CER)
EBITDA(1) of € 991.1 million, +14.5%, margin on net revenue of 37.8%
Adjusted net income(2) of € 651.1 million, +14.5%, margin on net revenue of 24.9%
Net income of € 443.6 million, +6.5%
Free cash flow(4) of € 558.8 million, +€ 23.7 million reflecting strong EBITDA partially offset by U.S. inventory build-up, higher interests and income tax paid
Net debt(5) at € 2,037.3

RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%

Tue, 17 Feb 2026 12:18:00 -0500

Consolidated net revenue of € 2,618.4 million for full year 2025, +11.8% or +8.3% on a like-for-like basis(3) at constant exchange rates (CER)
EBITDA(1) of € 991.1 million, +14.5%, margin on net revenue of 37.8%
Adjusted net income(2) of € 651.1 million, +14.5%, margin on net revenue of 24.9%
Net income of € 443.6 million, +6.5%
Free cash flow(4) of € 558.8 million, +€ 23.7 million reflecting strong EBITDA partially offset by U.S. inventory build-up, higher interests and income tax paid
Net debt(5) at € 2,037.3

RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%

Tue, 17 Feb 2026 12:18:00 -0500

Consolidated net revenue of € 2,618.4 million for full year 2025, +11.8% or +8.3% on a like-for-like basis(3) at constant exchange rates (CER)
EBITDA(1) of € 991.1 million, +14.5%, margin on net revenue of 37.8%
Adjusted net income(2) of € 651.1 million, +14.5%, margin on net revenue of 24.9%
Net income of € 443.6 million, +6.5%
Free cash flow(4) of € 558.8 million, +€ 23.7 million reflecting strong EBITDA partially offset by U.S. inventory build-up, higher interests and income tax paid
Net debt(5) at € 2,037.3

RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%

Tue, 17 Feb 2026 12:18:00 -0500

Consolidated net revenue of € 2,618.4 million for full year 2025, +11.8% or +8.3% on a like-for-like basis(3) at constant exchange rates (CER)
EBITDA(1) of € 991.1 million, +14.5%, margin on net revenue of 37.8%
Adjusted net income(2) of € 651.1 million, +14.5%, margin on net revenue of 24.9%
Net income of € 443.6 million, +6.5%
Free cash flow(4) of € 558.8 million, +€ 23.7 million reflecting strong EBITDA partially offset by U.S. inventory build-up, higher interests and income tax paid
Net debt(5) at € 2,037.3

RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%

Tue, 17 Feb 2026 12:18:00 -0500

Consolidated net revenue of € 2,618.4 million for full year 2025, +11.8% or +8.3% on a like-for-like basis(3) at constant exchange rates (CER)
EBITDA(1) of € 991.1 million, +14.5%, margin on net revenue of 37.8%
Adjusted net income(2) of € 651.1 million, +14.5%, margin on net revenue of 24.9%
Net income of € 443.6 million, +6.5%
Free cash flow(4) of € 558.8 million, +€ 23.7 million reflecting strong EBITDA partially offset by U.S. inventory build-up, higher interests and income tax paid
Net debt(5) at € 2,037.3

RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%

Tue, 17 Feb 2026 12:18:00 -0500

Consolidated net revenue of € 2,618.4 million for full year 2025, +11.8% or +8.3% on a like-for-like basis(3) at constant exchange rates (CER)
EBITDA(1) of € 991.1 million, +14.5%, margin on net revenue of 37.8%
Adjusted net income(2) of € 651.1 million, +14.5%, margin on net revenue of 24.9%
Net income of € 443.6 million, +6.5%
Free cash flow(4) of € 558.8 million, +€ 23.7 million reflecting strong EBITDA partially offset by U.S. inventory build-up, higher interests and income tax paid
Net debt(5) at € 2,037.3

RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%

Tue, 17 Feb 2026 12:18:00 -0500

Consolidated net revenue of € 2,618.4 million for full year 2025, +11.8% or +8.3% on a like-for-like basis(3) at constant exchange rates (CER)
EBITDA(1) of € 991.1 million, +14.5%, margin on net revenue of 37.8%
Adjusted net income(2) of € 651.1 million, +14.5%, margin on net revenue of 24.9%
Net income of € 443.6 million, +6.5%
Free cash flow(4) of € 558.8 million, +€ 23.7 million reflecting strong EBITDA partially offset by U.S. inventory build-up, higher interests and income tax paid
Net debt(5) at € 2,037.3

RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%

Tue, 17 Feb 2026 12:18:00 -0500

Consolidated net revenue of € 2,618.4 million for full year 2025, +11.8% or +8.3% on a like-for-like basis(3) at constant exchange rates (CER)
EBITDA(1) of € 991.1 million, +14.5%, margin on net revenue of 37.8%
Adjusted net income(2) of € 651.1 million, +14.5%, margin on net revenue of 24.9%
Net income of € 443.6 million, +6.5%
Free cash flow(4) of € 558.8 million, +€ 23.7 million reflecting strong EBITDA partially offset by U.S. inventory build-up, higher interests and income tax paid
Net debt(5) at € 2,037.3

RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%

Tue, 17 Feb 2026 12:18:00 -0500

Consolidated net revenue of € 2,618.4 million for full year 2025, +11.8% or +8.3% on a like-for-like basis(3) at constant exchange rates (CER)
EBITDA(1) of € 991.1 million, +14.5%, margin on net revenue of 37.8%
Adjusted net income(2) of € 651.1 million, +14.5%, margin on net revenue of 24.9%
Net income of € 443.6 million, +6.5%
Free cash flow(4) of € 558.8 million, +€ 23.7 million reflecting strong EBITDA partially offset by U.S. inventory build-up, higher interests and income tax paid
Net debt(5) at € 2,037.3

RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%

Tue, 17 Feb 2026 12:18:00 -0500

Consolidated net revenue of € 2,618.4 million for full year 2025, +11.8% or +8.3% on a like-for-like basis(3) at constant exchange rates (CER)
EBITDA(1) of € 991.1 million, +14.5%, margin on net revenue of 37.8%
Adjusted net income(2) of € 651.1 million, +14.5%, margin on net revenue of 24.9%
Net income of € 443.6 million, +6.5%
Free cash flow(4) of € 558.8 million, +€ 23.7 million reflecting strong EBITDA partially offset by U.S. inventory build-up, higher interests and income tax paid
Net debt(5) at € 2,037.3

RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%

Tue, 17 Feb 2026 12:18:00 -0500

Consolidated net revenue of € 2,618.4 million for full year 2025, +11.8% or +8.3% on a like-for-like basis(3) at constant exchange rates (CER)
EBITDA(1) of € 991.1 million, +14.5%, margin on net revenue of 37.8%
Adjusted net income(2) of € 651.1 million, +14.5%, margin on net revenue of 24.9%
Net income of € 443.6 million, +6.5%
Free cash flow(4) of € 558.8 million, +€ 23.7 million reflecting strong EBITDA partially offset by U.S. inventory build-up, higher interests and income tax paid
Net debt(5) at € 2,037.3

RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%

Tue, 17 Feb 2026 12:18:00 -0500

Consolidated net revenue of € 2,618.4 million for full year 2025, +11.8% or +8.3% on a like-for-like basis(3) at constant exchange rates (CER)
EBITDA(1) of € 991.1 million, +14.5%, margin on net revenue of 37.8%
Adjusted net income(2) of € 651.1 million, +14.5%, margin on net revenue of 24.9%
Net income of € 443.6 million, +6.5%
Free cash flow(4) of € 558.8 million, +€ 23.7 million reflecting strong EBITDA partially offset by U.S. inventory build-up, higher interests and income tax paid
Net debt(5) at € 2,037.3

RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%

Tue, 17 Feb 2026 12:18:00 -0500

Consolidated net revenue of € 2,618.4 million for full year 2025, +11.8% or +8.3% on a like-for-like basis(3) at constant exchange rates (CER)
EBITDA(1) of € 991.1 million, +14.5%, margin on net revenue of 37.8%
Adjusted net income(2) of € 651.1 million, +14.5%, margin on net revenue of 24.9%
Net income of € 443.6 million, +6.5%
Free cash flow(4) of € 558.8 million, +€ 23.7 million reflecting strong EBITDA partially offset by U.S. inventory build-up, higher interests and income tax paid
Net debt(5) at € 2,037.3

RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%

Tue, 17 Feb 2026 12:18:00 -0500

Consolidated net revenue of € 2,618.4 million for full year 2025, +11.8% or +8.3% on a like-for-like basis(3) at constant exchange rates (CER)
EBITDA(1) of € 991.1 million, +14.5%, margin on net revenue of 37.8%
Adjusted net income(2) of € 651.1 million, +14.5%, margin on net revenue of 24.9%
Net income of € 443.6 million, +6.5%
Free cash flow(4) of € 558.8 million, +€ 23.7 million reflecting strong EBITDA partially offset by U.S. inventory build-up, higher interests and income tax paid
Net debt(5) at € 2,037.3

RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%

Tue, 17 Feb 2026 12:18:00 -0500

Consolidated net revenue of € 2,618.4 million for full year 2025, +11.8% or +8.3% on a like-for-like basis(3) at constant exchange rates (CER)
EBITDA(1) of € 991.1 million, +14.5%, margin on net revenue of 37.8%
Adjusted net income(2) of € 651.1 million, +14.5%, margin on net revenue of 24.9%
Net income of € 443.6 million, +6.5%
Free cash flow(4) of € 558.8 million, +€ 23.7 million reflecting strong EBITDA partially offset by U.S. inventory build-up, higher interests and income tax paid
Net debt(5) at € 2,037.3

RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%

Tue, 17 Feb 2026 12:18:00 -0500

Consolidated net revenue of € 2,618.4 million for full year 2025, +11.8% or +8.3% on a like-for-like basis(3) at constant exchange rates (CER)
EBITDA(1) of € 991.1 million, +14.5%, margin on net revenue of 37.8%
Adjusted net income(2) of € 651.1 million, +14.5%, margin on net revenue of 24.9%
Net income of € 443.6 million, +6.5%
Free cash flow(4) of € 558.8 million, +€ 23.7 million reflecting strong EBITDA partially offset by U.S. inventory build-up, higher interests and income tax paid
Net debt(5) at € 2,037.3

RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%

Tue, 17 Feb 2026 12:18:00 -0500

Consolidated net revenue of € 2,618.4 million for full year 2025, +11.8% or +8.3% on a like-for-like basis(3) at constant exchange rates (CER)
EBITDA(1) of € 991.1 million, +14.5%, margin on net revenue of 37.8%
Adjusted net income(2) of € 651.1 million, +14.5%, margin on net revenue of 24.9%
Net income of € 443.6 million, +6.5%
Free cash flow(4) of € 558.8 million, +€ 23.7 million reflecting strong EBITDA partially offset by U.S. inventory build-up, higher interests and income tax paid
Net debt(5) at € 2,037.3

RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%

Tue, 17 Feb 2026 12:18:00 -0500

Consolidated net revenue of € 2,618.4 million for full year 2025, +11.8% or +8.3% on a like-for-like basis(3) at constant exchange rates (CER)
EBITDA(1) of € 991.1 million, +14.5%, margin on net revenue of 37.8%
Adjusted net income(2) of € 651.1 million, +14.5%, margin on net revenue of 24.9%
Net income of € 443.6 million, +6.5%
Free cash flow(4) of € 558.8 million, +€ 23.7 million reflecting strong EBITDA partially offset by U.S. inventory build-up, higher interests and income tax paid
Net debt(5) at € 2,037.3

RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%

Tue, 17 Feb 2026 12:18:00 -0500

Consolidated net revenue of € 2,618.4 million for full year 2025, +11.8% or +8.3% on a like-for-like basis(3) at constant exchange rates (CER)
EBITDA(1) of € 991.1 million, +14.5%, margin on net revenue of 37.8%
Adjusted net income(2) of € 651.1 million, +14.5%, margin on net revenue of 24.9%
Net income of € 443.6 million, +6.5%
Free cash flow(4) of € 558.8 million, +€ 23.7 million reflecting strong EBITDA partially offset by U.S. inventory build-up, higher interests and income tax paid
Net debt(5) at € 2,037.3

Recordati partners with Moderna on rare disease treatment mRNA-3927

Thu, 29 Jan 2026 17:20:08 -0500

Recordati (XMIL: REC) announced a collaboration and license agreement with Moderna to develop and commercialize mRNA-3927, an investigational treatment for propionic acidemia, a rare inherited metabolic disorder.

Under the agreement, Moderna will continue leading development of mRNA-3927 while Recordati will handle global commercialization if the treatment receives approval. Recordati will pay Moderna $50 million upfront and up to $110 million in near-term development and regulatory milestones. Moderna is also eligible for commercial milestones and tiered royalties on annual net sales.

mRNA-3927 targets propionic acidemia, which affects 1 in 100,000-150,000 individuals worldwide. The disorder is caused by defective mitochondrial enzymes leading to toxic

Recordati partners with Moderna on rare disease treatment mRNA-3927

Thu, 29 Jan 2026 17:20:08 -0500

Recordati (XMIL: REC) announced a collaboration and license agreement with Moderna to develop and commercialize mRNA-3927, an investigational treatment for propionic acidemia, a rare inherited metabolic disorder.

Under the agreement, Moderna will continue leading development of mRNA-3927 while Recordati will handle global commercialization if the treatment receives approval. Recordati will pay Moderna $50 million upfront and up to $110 million in near-term development and regulatory milestones. Moderna is also eligible for commercial milestones and tiered royalties on annual net sales.

mRNA-3927 targets propionic acidemia, which affects 1 in 100,000-150,000 individuals worldwide. The disorder is caused by defective mitochondrial enzymes leading to toxic

Recordati partners with Moderna on rare disease treatment mRNA-3927

Thu, 29 Jan 2026 17:20:08 -0500

Recordati (XMIL: REC) announced a collaboration and license agreement with Moderna to develop and commercialize mRNA-3927, an investigational treatment for propionic acidemia, a rare inherited metabolic disorder.

Under the agreement, Moderna will continue leading development of mRNA-3927 while Recordati will handle global commercialization if the treatment receives approval. Recordati will pay Moderna $50 million upfront and up to $110 million in near-term development and regulatory milestones. Moderna is also eligible for commercial milestones and tiered royalties on annual net sales.

mRNA-3927 targets propionic acidemia, which affects 1 in 100,000-150,000 individuals worldwide. The disorder is caused by defective mitochondrial enzymes leading to toxic

Recordati partners with Moderna on rare disease treatment mRNA-3927

Thu, 29 Jan 2026 17:20:08 -0500

Recordati (XMIL: REC) announced a collaboration and license agreement with Moderna to develop and commercialize mRNA-3927, an investigational treatment for propionic acidemia, a rare inherited metabolic disorder.

Under the agreement, Moderna will continue leading development of mRNA-3927 while Recordati will handle global commercialization if the treatment receives approval. Recordati will pay Moderna $50 million upfront and up to $110 million in near-term development and regulatory milestones. Moderna is also eligible for commercial milestones and tiered royalties on annual net sales.

mRNA-3927 targets propionic acidemia, which affects 1 in 100,000-150,000 individuals worldwide. The disorder is caused by defective mitochondrial enzymes leading to toxic

RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA

Thu, 29 Jan 2026 17:19:00 -0500

mRNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolio

Collaboration combines Moderna’s expertise in mRNA technology for rare metabolic disorders with Recordati’s established global rare disease commercial infrastructure

Moderna will continue to lead development for mRNA-3927, and if approved, Recordati will lead global commercialization efforts

Milan, 29 January 2026 – Recordati today announced that it has entered into a collaboration and license agreement with Moderna to develop and commercialize worldwide mRNA-3927, an investigational product for the treatment of propionic acidemia (PA). Under the terms of the agreement, Moderna will continue to